<DOC>
	<DOCNO>NCT02683577</DOCNO>
	<brief_summary>The purpose protocol ass pharmacokinetics , safety tolerability single dose telotristat etiprate subject various stage hepatic impairment compare healthy control subject .</brief_summary>
	<brief_title>Study Evaluate Dose Telotristat Etiprate Male Female With Mild , Moderate Severe Hepatic Insufficiency Matched Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Body mass index ( BMI ) 18 34 kg/mÂ² , inclusive , screen . BMI 35 may accept case 3point score ascites . Minimum body weight 50 kg . Vital sign ( 5 minute rest supine position ) within study specify range Female subject childbearing potential must agree use adequate doublebarrier method contraception study 30 day discharge . Subjects impaired hepatic function : Clinical diagnosis chronic hepatic disease ( stable 3 month ) document history underlie hepatic insufficiency acute episodes illness within 30 day prior Day 1 , significant change disease status ( ie , 1 point ChildPugh classification ) screen Day 1 . Control subject normal hepatic function : Clinical laboratory test result must strictly within normal laboratory reference range liver function , mean corpuscular volume ( MCV ) , parameter , deem clinically significant investigator . Presence clinically significant physical , laboratory , Electrocardiogram ( ECG ) finding ( exception parameter result underlying hepatic disease ) , opinion investigator , may interfere aspect study conduct interpretation result . Clinically significant illness disease determine medical history , include cardiac , pulmonary , hepatic ( reason hepatic impairment ) , biliary , Gastrointestinal ( GI ) , endocrinologic , renal disorder , cancer within last 5 year ( except localise situ nonmelanoma skin cancer ) , physical examination , clinical laboratory test , 12lead ECGs . Receipt investigational agent study drug within 30 day 10 halflives , whichever longer , prior dose . Smoking 20 cigarette ( eg , 1 pack ) per day equivalent ( eg , evapour cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) ; unable unwilling refrain smoking tobacco use 2 hour prior dose 4 hour dose administration . History serious adverse reaction hypersensitivity inactive component telotristat etiprate ( ie , microcrystalline cellulose , croscarmellose sodium ( disintegrant ) , talc , silicon dioxide , magnesium stearate ( nonbovine ) ) . Existence surgical medical condition , judgment investigator sponsor 's , medical monitor , might interfere absorption , distribution , metabolism , excretion telotristat etiprate . History major surgery within 6 month anticipate surgery prior Day 1 . History renal disease significantly abnormal kidney function test . History active infection within 30 day prior Day 1 , deem clinically significant investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>